Novo Nordisk A/S: Oral semaglutide 50 mg achieved 15.1% weight loss (17.4% if all people adhered to treatment) in adults with obesity or overweight in the OASIS 1 trial
Studies have shown many benefits in addition to weight loss- cardiac benefits, slower progression of dementia, lowers asthma, improves fatty liver, helps with knee osteoarthritis and more
However, securing Medicare coverage for insulin and related supplies, like needles and syringes, can be difficult for healthcare providers
Any product claiming to be retatrutide sold outside of an authorised clinical trial setting should be treated with significant caution, as it would be unlicensed and potentially unsafe
One of our top-selling materials is CJC-1295 with and without DAC
Amplifies insulin release, may modulate fat metabolism